Biogen recruits Novartis researcher to run ALS initiative; Concert bags a $2M milestone;

@FierceBiotech: Banking on its R&D rep, Calithera looks to raise $80M in IPO. News | Follow @FierceBiotech

@JohnCFierce: Kite Pharma soars on early evidence that CAR-T treatment quells cancer. Report | Follow @JohnCFierce

@EmilyMFierce: Cubist exec: Challenges mount in antibiotics discovery. FierceBiotech Research report | Follow @EmilyMFierce

> Biogen Idec has poached Donald R. Johns from Novartis ($NVS) to run its new ALS research hub. Release

> Lexington, MA-based Concert Pharmaceuticals ($CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals for the clinical progression of AVP-786. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Chinese physicians implant first 3-D printed vertebrae in child. Article | Follow @FierceMedDev

@VarunSaxena2: RT @FierceMedicalDevices: FDA simplifies approval process for innovative devices lacking a predecessor. Story | Follow @VarunSaxena2

@EmilyWFierce: Richard III was a foodie, according to a recent chemical analysis of the medieval king's teeth. NYT story | Follow @EmilyWFierce

> Researchers develop implant/app combo to monitor glaucoma in aging eyes. Story

> Philips Lifeline adds emergency response app to its service. Article

> Medtronic snags FDA approval for next-generation pacemaker. Report

Pharma News

@FiercePharma: Top-read on FierceAnimalHealth Monday: Merck releases tilapia vaccine. Article | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim opens a $30M packaging plant for its Vetmedica animal health biz. FierceAnimalHealth story | Follow @EricPFierce

@CarlyHFierce: Great news for those who have always wanted to hear me moderate a webinar: You're getting another chance. Register | Follow @CarlyHFierce

> Valeant's deal show goes on with $25M dermatology buy. Story

> Galena says goodbye to ex-CEO, no severance pay included. Article

> China's Luye Pharma founder soars into pharma's billionaire echelon. Report

Biotech Research News

> Cubist exec: Challenges mount in antibiotics discovery. Editor's Corner

> Tuberculosis biomarker predicts protection against disease symptoms. Article

> Scientists engineer opiate pain medicine without using poppies. Story

> Thymus gland grown from reprogrammed cells in lab. More

> Study: Early barriers in drug development are widespread. Report

Pharma Manufacturing News

> Sources: Ranbaxy's manufacturing problems lead to Texas. News

> Lupin took hard look at troubled Wockhardt for possible bid. More

> Alexion gets new Form 483 in follow-up inspection. Article

> Lonza looks to biotech funders for entree to business. Story

> Teva recalls Parkinson's disease drug because it may be 'superpotent.' Report

> PSC buys high-potency fill-finish facility from U.S. research group. Item

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…

J&J plans to have a vaccine in the clinic by September and win emergency use authorization early next year.